Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. - Wikidata - awgldk - TriplyDB

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

http://www.wikidata.org/entity/Q37955286

about

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.Vancomycin revisited - 60 years later Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Telavancin: a review of its use in patients with nosocomial pneumonia.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.

P2860

Q28078557-B3C3F7B1-3D56-4AD8-A09F-FDC941467B1A Q33429168-7A77F91F-B66E-43E0-8638-677819E6687E Q33788308-D679FB99-0A32-4443-AD4A-0035EEF9F2AE Q34390763-1C051C97-CC4C-43B8-BA7C-17B53E56EA6F Q34433066-1B6193E5-89FB-4964-B5C5-6C3937037B9A Q35905561-D3547555-1014-4DB9-AE1E-94A1810E3FEC Q38159966-BE68758A-8807-4DA0-A143-BBAECA57BA9B Q38522574-6A53C817-5139-42F5-96E9-A6D43D1AE145

P2860

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

http://www.wikidata.org/entity/Q37955286

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@en

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@nl

type

label

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@en

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@nl

prefLabel

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@en

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@nl

P1433

Q37955286-71FBE366-1253-4D25-9662-855415D1D91D

P1476

Q37955286-783B74B8-AFA6-4B8C-A6A4-16ABC2129C09

P2093

Q37955286-30D215A6-6F66-4FB9-9DD5-1A024128666E

Q37955286-4B4A4670-CFC0-4648-9953-6F47ACEEC4A9

Q37955286-6198AA58-C101-4269-AC72-35C8446E76C8

Q37955286-72BD2324-57EB-41B5-8CEE-867A49D0C1F5

P2860

Q37955286-045C9CC5-4957-4B9A-BB90-9979D7BCB13E

Q37955286-0839AFEE-A3C2-4414-A9EB-4E70E7EDDA32

Q37955286-0B27D938-14B1-466B-A673-3CBF4646504E

Q37955286-0DAE1AB1-CD2A-4DAA-9817-C21A13C93577

Q37955286-0DC147EB-38CD-4A0F-A1C7-E1673711CC93

Q37955286-111B7DCD-ED23-42CC-89D3-842BA9F1BB55

Q37955286-11FA623A-A7B7-41CF-AD01-475404B51FBF

Q37955286-234CB721-2DCA-41C6-98C1-AAC889900DD7

Q37955286-23A82A0D-9BCE-43BA-B0BA-545DAC12ACAB

Q37955286-2605CDF3-B1B4-4ACF-B5D4-7C66F81F2E0E

P304

Q37955286-F4EECE73-EAAE-4E90-A674-12D6FCBB5035

P31

Q37955286-76153F4E-103F-4854-9581-C49552FC70AD

P356

Q37955286-F279B002-6F02-4A4A-A6AF-0D084E8E16C3

P407

Q37955286-F82DA868-5300-448D-8CEB-4CF1E8523E5B

P433

Q37955286-3533AEAC-FABA-4218-8750-127CC008DB3A

P478

Q37955286-77A83100-FD42-4F07-A72D-DB56DE07BCE1

P577

Q37955286-3DC9EF57-1A70-4B06-BAC3-EFBB4FC2C020

P698

Q37955286-C557718A-B9C9-4A2D-B70D-AFE924FEE27A

P921

Q37955286-7846E2B8-3C9E-4C71-B3A4-EA6B57CB90BA

Q37955286-CB6BCDB1-3410-44FE-B973-FB0365B8ED22

P356

14656566.2011.633511

P1433

Expert Opinion on Pharmacotherapy

P1476

Telavancin for the treatment o ...... g hospital acquired pneumonia.

@en

P2093

Ethan Rubinstein

http://www.w3.org/2001/XMLSchema#string

G Ralph Corey

http://www.w3.org/2001/XMLSchema#string

Martin E Stryjewski

http://www.w3.org/2001/XMLSchema#string

Zeina A Kanafani

http://www.w3.org/2001/XMLSchema#string

P2860

Red man syndrome

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis.

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Intrapulmonary pharmacokinetics of linezolid

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

P304

2737-2750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.633511

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22077833

http://www.w3.org/2001/XMLSchema#string

P921

Gram-positive bacteria